Parkinson's Disease Genes Do Not Segregate with Breast Cancer Genes' Loci

Kravitz, Efrat; Laitman, Yael; Hassin‐Baer, Sharon; Inzelberg, Rivka; Friedman, Eitan

doi:10.1158/1055-9965.epi-13-0472

Cited by 3 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the prevalence of LRRK2 G2019S varies widely by population 17,18,23 , and in the United Kingdom the frequency of this mutation is very low. Another investigation 31 of 188 breast cancer-associated single-nucleotide polymorphisms from genome-wide association studies also did not find cosegregation with PD susceptibility loci, including LRRK2 . By contrast, colon cancer appeared to be increased in LRRK2 R1441G/C mutation carriers without PD 21 .…”

Section: Discussionmentioning

confidence: 93%

“…Although we did not have complete information on the BRCA1/BRCA2 mutation status of all women with PD, investigators at Sheba Medical Center 19 evaluated mutations in their breast cancer cases and found only a single BRCA1 mutation that cosegregated with the LRRK2 G2019S mutation. They separately analyzed genome-wide association study data evaluating breast cancer single-nucleotide polymorphisms in relationship to PD genes and found no suggestion of simple cosegregation or shared genetic loci 31 . Thus, the association between LRRK2 G2019S mutation and breast cancer is unlikely to be the result of confounding by BRCA1/BRCA2 mutation-carrier status, but this cannot be fully ruled out without genotyping all breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Higher Frequency of Certain Cancers inLRRK2G2019S Mutation Carriers With Parkinson Disease

et al. 2015

Self Cite

View full text Add to dashboard Cite

disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies.OBJECTIVES To analyze pooled data from 5 centers to further examine the association between LRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies. DESIGN, SETTING, AND PARTICIPANTS Clinical, demographic, and genotyping data as well as cancer outcomes were pooled from 1549 patients with PD recruited across 5 movement disorders clinics located in Europe, Israel, and the United States. Associations between LRRK2 G2019S mutation and the outcomes were examined using mixed-effects logistic regression models to estimate odds ratios (ORs) and 95% CIs. Models were adjusted for age and ethnicity (Ashkenazi Jewish vs others) as fixed effects and study center as a random effect. MAIN OUTCOMES AND MEASURESAll cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer. RESULTSThe overall prevalence of the LRRK2 G2019S mutation was 11.4% among all patients with PD. Mutation carriers were younger at PD diagnosis and more likely to be women (53.1%) and of Ashkenazi Jewish descent (76.8%) in comparison with individuals who were not mutation carriers. The LRRK2 G2019S mutation carriers had statistically significant increased risks for nonskin cancers (OR, 1.62; 95% CI, 1.04-2.52), hormone-related cancers (OR, 1.87; 95% CI, 1.07-3.26) and breast cancer (OR, 2.34; 95% CI, 1.05-5.22) in comparison with noncarriers. There were no associations with other cancers. There were no major statistically significant differences in the results when the data were stratified by Ashkenazi Jewish ethnicity; however, there was some evidence of heterogeneity across centers.CONCLUSIONS AND RELEVANCE This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. Larger prospective cohorts or family-based studies investigating associations between LRRK2 mutations and cancer among patients with PD are warranted to better understand the underlying genetic susceptibility between PD and hormone-related cancers.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Higher Frequency of Certain Cancers inLRRK2G2019S Mutation Carriers With Parkinson Disease

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…In a study from 2013, Kravitz et al, did not find any association related to the genetic inheritance among breast cancer polymorphisms of single-nucleotide and predisposition genetic code of Parkinson's disease (39).…”

Section: Prostate and Breast Cancermentioning

confidence: 96%

Cancer in Parkinson’s Disease, a Review of Literature

Zorina

2021

ARS Medica Tomitana

View full text Add to dashboard Cite

Background/Aim: The present study aimed to assess the conclusions of literature articles on the matter of cancer in Parkinson’s disease. Patients and Methods: Studies and articles that contained information on epidemiology, pathophysiological, clinical as well as associations and correlations on the topic of Parkinson’s disease and cancer were incorporated in the research too. Results: The prevalent part of the investigations and studies on the matter of Parkinson’s disease patients’ risk of cancer revealed a decreased lifetime risk in comparisson with non-PD subjects. In the literature, the most prevalent types of cancer among Parkinson’s disease patients were melanoma and other subtypes skin cancer and also, breast cancer. Conclusion: Epigenetic factors, gene–environment interactions, and problematic events can have an impact in the occurance and progression of Parkinson’s disease. Further, the mentioned factors can also determine the developing of cancer. Therefore, a complex and interesting relation between the two diseases is further to be discovered.

show abstract